Imagine if we could inhale scents that delay the onset of cancer, inflammation, or neurodegenerative disease. Researchers at the University of California, Riverside, are poised to bring this ...
Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...
Pancreatic cancer is one of the deadliest cancers - only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall ...
A new research paper titled "Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy" has ...
It's our newest approach on the block in terms of approval. So I think we're still understanding it as a community because it's relatively recent, but the clinical trial work certainly did show ...
Simultaneous inhibition of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) is considered a good strategy in cancer treatment, although current PI3K/HDAC dual inhibitors have ...
Histone deacetylase (HDAC) inhibitors represent a promising class of antimalarial agents by targeting the epigenetic machinery of Plasmodium species. By blocking HDAC activity, these compounds induce ...
A drug with a past life as a potential anti-cancer agent might someday have a new job as "the pill" for men, new data in mice suggest. In a journal article published Feb. 20 in Proceedings of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results